araag2/HINT huggingface dataset:
Clinical trial NCT00429702 (phase 2, status: terminated)
Conditions: nausea, vomiting, unspecified childhood solid tumor, protocol specific
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: decadron®, benadryl®, ativan®, ondansetron hydrochloride
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1, OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    closed due to poor accrual and lack of feasibility to finish study per dsmb
  
Eligibility criteria:

        INCLUSION CRITERIA:

          -  ≥ 8 years of age and < 19 years of age at the time of registration

          -  Newly diagnosed with cancer

          -  Chemotherapy naive

          -  Scheduled to receive moderately or highly emetogenic chemotherapy (non-steroid
             containing regimen) as an in-patient. (Refer to Appendix IV. In multiple agent
             regimens, select the agent with the highest emetic potential.)

          -  Scheduled for placement of IV accesses device(s) for treatment purposes (allowing a
             dedicated line for continuous infusion of study agent)

          -  Not pregnant or lactating

        EXCLUSION CRITERIA:

          -  Prior chemotherapy

          -  Central Nervous System disease

          -  Stem cell transplant while on-study

          -  Out-patient chemotherapy

          -  Steroids are included in their chemotherapy regimen

          -  Contraindication to the use of dexamethasone (e.g. diabetes)

          -  Hepatic and/or renal failure

          -  Allergic to any of the study medications

          -  Pregnant or lactating
Clinical trial NCT00389688 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, pemetrexed disodium
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed non-small cell lung cancer (NSCLC)

               -  Stage IB or II disease

          -  Resectable disease

          -  At least 1 measurable lesion

          -  No mediastinal involvement by mediastinoscopy and/or positron emission tomography with
             fludeoxyglucose F 18 scan

          -  No evidence of metastatic disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Absolute neutrophil count > 1,500/mm³

          -  Platelet count > 100,000/mm³

          -  Hemoglobin > 10 g/dL

          -  Creatinine clearance ≥ 60 mL/min

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 3.0 times ULN

          -  AST and ALT ≤ 3.0 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignant disease, except for the following:

               -  Basocellular carcinoma of the skin

               -  Adequately treated carcinoma in situ of the cervix

               -  Low-grade prostate cancer

               -  Other cancer for which the patient has been disease-free for ≥ 5 years

          -  No congestive heart failure or angina pectoris unless medically controlled

          -  No myocardial infarction within the past 6 months

          -  No uncontrolled hypertension or arrhythmia

          -  No active uncontrolled infection requiring antibiotics

          -  No illness or medical condition that would preclude study participation

          -  No pre-existing motor or sensory neurotoxicity ≥ grade 2

        PRIOR CONCURRENT THERAPY:

          -  No prior surgery for NSCLC

          -  No prior or other concurrent chemotherapy for NSCLC

          -  No prior or concurrent radiotherapy for NSCLC

          -  No concurrent immunotherapy

          -  No concurrent targeted agents

          -  No concurrent hormonal cancer therapy

          -  No concurrent routine colony-stimulating factor (e.g., prophylactic filgrastim
             [G-CSF])

          -  No aspirin or nonsteroidal anti-inflammatory drugs within 5 days before or after
             chemotherapy

          -  No other concurrent experimental treatments

          -  No other concurrent anticancer treatments
Clinical trial NCT00234078 (phase 2, status: completed)
Conditions: dry eye syndromes
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: 0.5% opc-12759, 1% opc-12759, 2% opc-12759, placebo
SMILES: OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1, OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1, OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Outpatient.

          2. Subjective complaint of dry eye that has been present for minimum 20 months.

          3. Primary ocular discomfort severity is moderate to severe.

          4. Corneal - conjunctival damage is moderate to severe.

          5. Unanesthetized Schirmer's test score of 7mm/5minutes or less.

          6. Best corrected visual acuity of 0.2 or better in both eyes.

        Exclusion Criteria:

          1. Presence of anterior segment disease or disorder other than that associated with
             keratoconjunctivitis sicca.

          2. Anticipated use of any topically-instilled ocular medications or patients with cannot
             discontinue the use during the study.

          3. Anticipated use of contact lens during the study.

          4. Any history of ocular surgery within 12 months.

          5. Female patients who are pregnant, possibly pregnant or breast feeding;

          6. Known hypersensitivity to any component of the study drug or procedural medications.

          7. Receipt of any investigational product within 4 months.
Clinical trial NCT00334568 (phase 2, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: rosiglitazone xr (extended release) oral tablets, placebo
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Meets the National Institute of Neurological and Communicative Diseases and
             Stroke/Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) criteria
             for Alzheimers disease, regardless of date of diagnosis relative to study entry date.

          -  Has an Alzheimers disease status of mild to moderate, as classified by a Mini Mental
             State Examination (MMSE) score of 16 - 26 inclusive at screening.

          -  Post-menopausal females defined as menopause is defined as >6 months without menstrual
             period with an appropriate clinical profile, e.g. age appropriate, history of
             vasomotor symptoms. However if indicated this should be confirmed by oestradiol and
             FSH levels consistent with menopause (according to local laboratory ranges).

          -  Women who are on HRT (hormone replacement therapy) treatment, and have not been
             confirmed as post-menopausal should be advised to use contraception.

          -  Has a permanent caregiver who is willing to attend all visits, oversee the subjects
             compliance with protocol-specified procedures and study medication, and report on
             subjects status. (Subjects living alone or in a nursing home are not eligible).

        Exclusion Criteria:

          -  Has a history of or suffers from claustrophobia.

          -  Is unable to lie comfortably on a bed inside a PET camera with their head in the field
             of view for at least 60 minutes as assessed by physical examination and medical
             history (e.g. back pain, arthritis).

          -  Has a history or presence of other neurological or other medical conditions that may
             influence the outcome or analysis of the PET scan results. Examples of such conditions
             include, but are not limited to stroke, traumatic brain injury, epilepsy or space
             occupying lesions.

          -  History of Type I or Type II diabetes mellitus.

          -  Fasting plasma glucose level >126 mg/dL (>7.0 mmol/L) or HbA1c >6.2%.

          -  History or clinical/laboratory evidence of moderate congestive heart failure defined
             by the New York Heart Association criteria (class II-IV.
Clinical trial NCT00313170 (phase 2, status: completed)
Conditions: advanced breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Breast Cancer has continued to grow after having received treatment with an
             anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.

          -  Requiring hormonal treatment.

          -  Postmenopausal women (woman who has stopped having menstrual periods)

        Exclusion Criteria:

          -  Treatment with more than one previous regimen of systemic anticancer therapy other
             than endocrine therapy for advanced BC.

          -  Treatment with more than one previous regimen of endocrine therapy for advanced BC.

          -  An existing condition that prevents compliance.
Clinical trial NCT00509184 (phase 2, status: completed)
Conditions: lymphoma, malignant
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  verified follicular lymphoma grade 1 or 2

          -  only nodal involvement (incl. Waldeyer) clinical stage I or II

          -  largest tumor ≤ 7 cm

          -  adequate bone marrow reserves

        Exclusion Criteria:

          -  ECOG >2

          -  Follicular lymphoma grade 3

          -  buky disease (>7 cm)

          -  involvement of the spleen

          -  neoplasia in PMH (except: basalioma, spinalioma)

          -  Immunodeficiency syndromes, viral hepatitis, connective tissue disease

          -  severe psychiatric disease

          -  pregnancy or breast feeding

          -  known allergies against foreign proteins
Clinical trial NCT00391118 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube neoplasms, peritoneal neoplasm
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02
Drugs: enzastaurin, carboplatin, paclitaxel, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have specific stages of disease, known as Fédération Internationale
             de Gynécologie et d'Obstétrique (FIGO) stages IIB, IIC, III or IV

          -  Organ functions (blood, renal, liver, cardiac) must meet specific requirements.

          -  Participants who could become pregnant must take care not to become pregnant during
             the study participation and for 6 months after study discontinuation

          -  Participants must give written consent for study participation.

        Exclusion Criteria:

          -  Participants received any experimental drug within the last 30 days.

          -  Participants received any prior chemotherapy or other drug therapy for the current
             disease.

          -  Participants receive any other treatment for the cancer during study participation.

          -  Participants are unable to discontinue concurrent administration of carbamazepine,
             phenobarbital, or phenytoin.

          -  Participants are pregnant, breast feeding, or not using adequate contraceptive methods
             to prevent pregnancy.
Clinical trial NCT00351637 (phase 2, status: terminated)
Conditions: cancer, pain
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: sublingual methadone
SMILES: CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    study suspended due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pain due to cancer or its treatment; Controlled baseline pain; episodes of
             predictable, treatment related pain every day that are 4"/10" in severity or greater,
             last 10 minutes or longer, or episodes of breakthrough pain not related to cancer
             treatment, and are responsive to short acting oral opioids such as morphine or
             hydromorphone; are able to hold a volume of 1.0cc of water under tongue for a 2-minute
             period; are able to provide written informed consent; are able to fill out the study
             forms, and are inpatients

        Exclusion Criteria:

          -  Severe underlying respiratory disease such that the investigator is wary about the
             risk of respiratory failure from modest doses od opioid; prior sensitivity to
             methadone; currently are being administered methadone; are clinically unstable or have
             a life expectancy of less than one month making completion of the trial unlikely; and
             if they do not understand English sufficiently to provide written informed consent.
Clinical trial NCT01289132 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: placebo, azilsartan, azilsartan, azilsartan, azilsartan, azilsartan, candesartan cilexetil
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Has mild to moderate uncomplicated essential hypertension.

          -  Has a sitting diastolic blood pressure between 95 and <110 mmHg and sitting systolic
             blood pressure between 150 and <180 mmHg at placebo run-in period (Week -2) or
             randomization visit.

        Exclusion Criteria:

          -  Has a cardiovascular disease or symptoms

          -  Has been treated with more than 3 different antihypertensives within 27 days prior to
             placebo run-in period.

          -  Has a significant hepatic disorder, hyperkalemia, malignant tumor or significant renal
             impairment.
Clinical trial NCT00595413 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo matched to atacicept, atacicept: with loading dose, atacicept
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects greater than or equal to (>=) 18 years of age at the time of
             informed consent who have RA satisfying American College of Rheumatology (ACR)
             criteria with a disease history of at least 6 months

          -  Subjects must have active disease, defined by >=8 swollen joints (out of 66), >=8
             tender joints (out of 68) and CRP >=10 milligram per liter (mg/L) and/or erythrocyte
             sedimentation rate (ESR) >=28 millimeter per hour (mm/hr), despite treatment with MTX
             at a dose of >=15 milligram per week (mg/week) for greater than (>) 3 months

          -  Other protocol-defined inclusion criteria could apply

        Exclusion Criteria:

          -  Inflammatory joint disease other than RA

          -  Previous or concurrent treatment with any approved or investigational biological
             compound for RA, including but not restricted to any anti-TNFalpha agents, rituximab,
             abatacept, tocilizumab, interleukin-1 receptor antagonist (IL-1Ra) and belimumab

          -  Treatment with disease-modifying anti-rheumatic drug (DMARDs) other than MTX

          -  Participation in any interventional clinical trial within 1 month before study Day 1

          -  MTX dose >25 mg/week, prednisone dose >10 mg/day (or equivalent), or change in steroid
             or non-steroidal anti-inflammatory drug (NSAID) dosing regimen within 28 days before
             study Day 1

          -  Immunization with live vaccine or immunoglobulin (Ig) treatment within 28 days before
             study Day 1 or need for such treatment during the study (including follow-up)

          -  Any history or presence of active or latent tuberculosis, major infection requiring
             hospitalization or intravenous anti-infectives within 28 days before study Day 1

          -  Other major concurrent illness or organ dysfunction as specified in the protocol

          -  Serum IgG below 6 gram per liter (g/L)

          -  Known hypersensitivity to atacicept or to any of the components of the formulated
             atacicept

          -  Other protocol-defined exclusion criteria could apply
Clinical trial NCT00543400 (phase 2, status: completed)
Conditions: coronary artery disease (cad)
ICD codes: I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: m118, unfractionated heparin
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 19 years

          -  Ability to give informed consent

          -  Documented stable CAD with a significant lesion in a native coronary artery amenable
             to PCI with one stent

          -  Planned single vessel intervention

        Exclusion Criteria:

          -  Myocardial infarction or unstable angina within the prior 7 days

          -  Target lesion is a chronic total occlusion (present for longer than 3 months)

          -  Target lesion with angiographically visible thrombus or in-stent thrombosis

          -  Target lesion is in a bypass graft

          -  Planned use of a GP IIb/IIIa inhibitor or planned use of atherectomy including
             directional, rotational, or laser

          -  Known allergies or sensitivities to heparin, pork, or pork-containing products

          -  History of HIT

          -  Hemodynamic instability

          -  Stroke or Transient Ischemic Attack (TIA) in the prior 3 months

          -  Active bleeding or bleeding diathesis

          -  Trauma or major surgery in the preceding month or planned surgery or PCI within the 30
             days after the index PCI

          -  Suspected aortic dissection

          -  Receiving oral anticoagulation therapy

          -  Receipt of LMWH or of UFH (except for that used during the diagnostic portion of the
             index procedure) within the prior 7 days

          -  ACT > 200 prior to study drug administration

          -  Severe, untreated hypertension at the time of the index PCI procedure (systolic blood
             pressure of > 180 mm Hg, diastolic blood pressure > 90 mm Hg)

          -  Hemoglobin level of less than 10.0 g/dl or a hematocrit below 30%

          -  Platelet count of less than 100,000 per cubic millimeter or more than 600,000 per
             cubic millimeter

          -  Creatinine clearance < 30 mL/min

          -  Any malignancy within the prior 5 years with the exception of non-melanoma skin
             cancers

          -  Prior enrollment in EMINENCE trial or currently receiving other experimental therapy

          -  Pregnant or lactating if subject is female

        Substudy:

        Inclusion:

          -  Ability to give informed consent

          -  Participation in the main study protocol

        Exclusion:

        -Inability to provide the blood specimens required by the substudy protocol
Clinical trial NCT00256308 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    halted prematurely due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects must have histologically or cytologically confirmed diagnosis of squamous
             cell carcinoma of the head and neck region. Primary tumor sites include: oral cavity,
             pharynx (oropharynx, hypopharynx), or larynx (supraglottis, glottis subglottis).
             Nasopharynx primary will be excluded.

          -  The resected tumor must have one or more of the following high risk features:
             histologic extracapsular nodal extension involvement of ≥ 2 regional lymph nodes,
             mucosal margin of resection with invasive cancer (limited to microscopic detection
             only), tumor with perineural invasion, tumor with lymphovascular invasion, oral cavity
             and oropharynx carcinomas with positive lymph nodes metastasis at level IV or V.

          -  Radiation must begin within 28 to 56 days after surgical resection.

          -  All subjects must be 18 years of age or older.

          -  Subjects must have a Zubrod performance of 0-2.

        Exclusion Criteria:

          -  Subjects must not have distant metastatic disease (M1).

          -  Subjects must NOT have prior therapy with oxaliplatin.

          -  Subjects with any evidence of active or uncontrolled infection, recent myocardial
             infection, unstable angina, or life-threatening arrhythmia are not eligible.

          -  Patients with severe psychiatric disorder are not eligible.

          -  No other prior malignancy is allowed except for adequately treated basal cell or
             squamous cell carcinoma, in situ cervical cancer, or adequately treated Stage I and II
             cancer from which the patient is in complete remission, or any other malignancy from
             which the patient has been disease-free for 5 years.